448 related articles for article (PubMed ID: 10493279)
1. Topotecan: a review of its efficacy in small cell lung cancer.
Ormrod D; Spencer CM
Drugs; 1999 Sep; 58(3):533-51. PubMed ID: 10493279
[TBL] [Abstract][Full Text] [Related]
2. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.
von Pawel J; Schiller JH; Shepherd FA; Fields SZ; Kleisbauer JP; Chrysson NG; Stewart DJ; Clark PI; Palmer MC; Depierre A; Carmichael J; Krebs JB; Ross G; Lane SR; Gralla R
J Clin Oncol; 1999 Feb; 17(2):658-67. PubMed ID: 10080612
[TBL] [Abstract][Full Text] [Related]
3. Topotecan in the treatment of recurrent small cell lung cancer: an update.
Ardizzoni A
Oncologist; 2004; 9 Suppl 6():4-13. PubMed ID: 15616145
[TBL] [Abstract][Full Text] [Related]
4. Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.
Park SH; Cho EK; Kim Y; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Lee JI; Choi SJ; Park J; Shin DB; Lee JH
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1009-14. PubMed ID: 18259751
[TBL] [Abstract][Full Text] [Related]
5. [Topotecan: prospects for using it in combination therapy for ovarian carcinoma].
Scarfone G
Tumori; 1999; 85(6 Suppl 1):S12-5. PubMed ID: 10786195
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
Garst J; Herndon JE; Shafman T; Campagna L; Blackwell S; Padilla K; Bjurstrom T; Andrews C; Maravich-May D; Anderson E; Crawford J
Clin Drug Investig; 2006; 26(5):257-66. PubMed ID: 17163259
[TBL] [Abstract][Full Text] [Related]
7. Topotecan. A review of its potential in advanced ovarian cancer.
Brogden RN; Wiseman LR
Drugs; 1998 Oct; 56(4):709-23. PubMed ID: 9806112
[TBL] [Abstract][Full Text] [Related]
8. The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.
Loveman E; Jones J; Hartwell D; Bird A; Harris P; Welch K; Clegg A
Health Technol Assess; 2010 Mar; 14(19):1-204. PubMed ID: 20356561
[TBL] [Abstract][Full Text] [Related]
9. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
[TBL] [Abstract][Full Text] [Related]
10. Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer.
Riemsma R; Simons JP; Bashir Z; Gooch CL; Kleijnen J
BMC Cancer; 2010 Aug; 10():436. PubMed ID: 20716361
[TBL] [Abstract][Full Text] [Related]
11. Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.
Kollmannsberger C; Mross K; Jakob A; Kanz L; Bokemeyer C
Oncology; 1999; 56(1):1-12. PubMed ID: 9885371
[TBL] [Abstract][Full Text] [Related]
12. A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
Kakolyris S; Kouroussis C; Souglakos J; Mavroudis D; Agelaki S; Kalbakis K; Androulakis N; Vardakis N; Vamvakas L; Georgoulias V
Oncology; 2001; 61(4):265-70. PubMed ID: 11721172
[TBL] [Abstract][Full Text] [Related]
13. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.
Reck M; Groth G; Buchholz E; Goetz E; Gatzemeier U; Manegold C
Lung Cancer; 2005 Jun; 48(3):409-13. PubMed ID: 15893010
[TBL] [Abstract][Full Text] [Related]
14. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.
Ardizzoni A; Hansen H; Dombernowsky P; Gamucci T; Kaplan S; Postmus P; Giaccone G; Schaefer B; Wanders J; Verweij J
J Clin Oncol; 1997 May; 15(5):2090-6. PubMed ID: 9164222
[TBL] [Abstract][Full Text] [Related]
15. Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer.
Herben VM; ten Bokkel Huinink WW; Schot ME; Hudson I; Beijnen JH
Anticancer Drugs; 1998 Jun; 9(5):411-8. PubMed ID: 9660538
[TBL] [Abstract][Full Text] [Related]
16. New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors.
Huang CH; Treat J
Oncology; 2001; 61 Suppl 1():14-24. PubMed ID: 11598410
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline.
Cheng S; Evans WK; Stys-Norman D; Shepherd FA;
J Thorac Oncol; 2007 Apr; 2(4):348-54. PubMed ID: 17409809
[TBL] [Abstract][Full Text] [Related]
18. Emerging role of weekly topotecan in recurrent small cell lung cancer.
Eckardt JR
Oncologist; 2004; 9 Suppl 6():25-32. PubMed ID: 15616147
[TBL] [Abstract][Full Text] [Related]
19. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K;
Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
Ernani V; Jahan R; Smith LM; Marr AS; Kimbrough SE; Kos ME; Tijerina J; Pivovar S; Lakshmanan I; Ketcham M; Rauth S; Mallya K; Nasser MW; Jain M; Kessinger A; Batra SK; Ganti AK
Cancer Treat Res Commun; 2020; 22():100162. PubMed ID: 31675535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
